-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Short Interest in Artemis Therapeutics Inc. (OTCMKTS:ATMS) Decreases By 18.2%
Short Interest in Artemis Therapeutics Inc. (OTCMKTS:ATMS) Decreases By 18.2%
Artemis Therapeutics Inc. (OTCMKTS:ATMS – Get Rating) was the target of a significant decline in short interest during the month of September. As of September 15th, there was short interest totalling 900 shares, a decline of 18.2% from the August 31st total of 1,100 shares. Based on an average daily trading volume, of 1,200 shares, the short-interest ratio is presently 0.8 days.
Artemis Therapeutics Stock Performance
Shares of Artemis Therapeutics stock traded up $0.30 on Friday, hitting $3.00. 5,022 shares of the company's stock traded hands, compared to its average volume of 1,159. The firm's 50-day moving average price is $1.81 and its two-hundred day moving average price is $2.26. Artemis Therapeutics has a one year low of $0.55 and a one year high of $5.00.
Get Artemis Therapeutics alerts:About Artemis Therapeutics
(Get Rating)
Artemis Therapeutics Inc does not have significant operations. Previously, it was involved in the development of agents for the prevention and treatment of severe and life-threatening infectious diseases. The company is based in New York, New York. Artemis Therapeutics Inc is a subsidiary of Tonak Ltd.Read More
- Get a free copy of the StockNews.com research report on Artemis Therapeutics (ATMS)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Declining Profits Challenge the CarMax Value Proposition
- Thor Industries Hammers Out A Bottom
Receive News & Ratings for Artemis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artemis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Artemis Therapeutics Inc. (OTCMKTS:ATMS – Get Rating) was the target of a significant decline in short interest during the month of September. As of September 15th, there was short interest totalling 900 shares, a decline of 18.2% from the August 31st total of 1,100 shares. Based on an average daily trading volume, of 1,200 shares, the short-interest ratio is presently 0.8 days.
Artemis治疗公司(场外交易市场代码：ATMS-GET Rating)是空头股数9月份显著下降的目标。截至9月15日，空头股数共有900股，比8月31日的1100股下降了18.2%。以日均成交量1,200股计算，目前短息比为0.8天。
Artemis Therapeutics Stock Performance
Artemis治疗公司股票表现
Shares of Artemis Therapeutics stock traded up $0.30 on Friday, hitting $3.00. 5,022 shares of the company's stock traded hands, compared to its average volume of 1,159. The firm's 50-day moving average price is $1.81 and its two-hundred day moving average price is $2.26. Artemis Therapeutics has a one year low of $0.55 and a one year high of $5.00.
Artemis治疗公司的股票周五上涨0.30美元，达到3.00美元。该公司股票有5,022股易手，而其平均成交量为1,159股。该公司的50日移动均线价格为1.81美元，200日移动均线价格为2.26美元。Artemis Treeutics的一年低点为0.55美元，一年高位为5.00美元。
About Artemis Therapeutics
关于Artemis Treateutics
(Get Rating)
(获取评级)
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Artemis Therapeutics (ATMS)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Declining Profits Challenge the CarMax Value Proposition
- Thor Industries Hammers Out A Bottom
- 免费获取StockNews.com关于Artemis治疗(ATMS)的研究报告
- 电动汽车电池制造商Freyr将在全球大举扩张
- MarketBeat：回顾一周9/26-9/30
- 这是买入美光科技的难忘时刻
- 利润下降对CarMax价值主张的挑战
- 雷神工业走出谷底
Receive News & Ratings for Artemis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artemis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Artemis治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Artemis治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧